{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:10:20Z","timestamp":1769613020695,"version":"3.49.0"},"reference-count":28,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,8,21]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>This mini review describes some of the key interactions between cancer cells and the immune system. This includes the concept of tumour cell immunosurveillance, mechanisms of immune evasion by tumour cells and some of the novel immunology-based anticancer therapies that have recently been introduced. The latter are also set into the context of the enlarging spectrum of immunohistochemistry-based and molecular testing that can now be performed on formalin-fixed and paraffin-embedded tissues for predicting response to both well-established and newly developed agents. The emerging field of cancer immunotherapy requires and encourages close working between cellular and molecular pathology and clinical cancer treatment, while providing new hope for patients with cancers that may not have responded to conventional oncological treatments.<\/jats:p>","DOI":"10.1136\/jclinpath-2018-205370","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T12:15:25Z","timestamp":1538396125000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Molecules in cancer immunotherapy: benefits and side effects"],"prefix":"10.1136","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2222-4104","authenticated-orcid":false,"given":"Adrian C","family":"Bateman","sequence":"first","affiliation":[{"name":"Department of Cellular Pathology, Southampton General Hospital, Southampton SO16 6YD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"2025092506042897000_72.1.20.1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-016-3743-x","article-title":"Increased CD4 and CD8-positive t cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer","volume":"156","author":"Matsumoto","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2025092506042897000_72.1.20.2","doi-asserted-by":"crossref","unstructured":"Kim Y , Wen X , Bae JM , et al . The distribution of intratumoral macrophages correlates with molecular phenotypes and impacts prognosis in colorectal carcinoma. Histopathology 2018. doi:10.1111\/his.13674","DOI":"10.1111\/his.13674"},{"key":"2025092506042897000_72.1.20.3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/CAD.0000000000000526","article-title":"Spontaneous regression of malignant melanoma - is it based on the interplay between host immune system and melanoma antigens?","volume":"28","author":"Cervinkova","year":"2017","journal-title":"Anticancer Drugs"},{"key":"2025092506042897000_72.1.20.4","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328307ee4c"},{"key":"2025092506042897000_72.1.20.5","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1097\/DAD.0000000000000614","article-title":"Complete spontaneous regression of merkel cell carcinoma after biopsy: a case report and review of the literature","volume":"38","author":"Ahmadi Moghaddam","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"2025092506042897000_72.1.20.6","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0132"},{"key":"2025092506042897000_72.1.20.7","first-page":"30230","article-title":"Immunosurveillance of cancer and the heat shock protein-CD91 pathway","volume":"8749","author":"Binder","year":"2018","journal-title":"Cell Immunol"},{"key":"2025092506042897000_72.1.20.8","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12470"},{"key":"2025092506042897000_72.1.20.9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00054","article-title":"Mechanisms of immune evasion and immune modulation by lymphoma cells","volume":"8","author":"Menter","year":"2018","journal-title":"Front Oncol"},{"key":"2025092506042897000_72.1.20.10","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu076"},{"key":"2025092506042897000_72.1.20.11","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204853"},{"key":"2025092506042897000_72.1.20.12","first-page":"30626","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project","volume":"0864","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025092506042897000_72.1.20.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01230.x"},{"key":"2025092506042897000_72.1.20.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.10.005"},{"key":"2025092506042897000_72.1.20.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8770"},{"key":"2025092506042897000_72.1.20.16","doi-asserted-by":"crossref","unstructured":"Postow MA . Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015:76\u201383. doi:10.14694\/EdBook_AM.2015.35.76","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"2025092506042897000_72.1.20.17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv227"},{"key":"2025092506042897000_72.1.20.18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/his.13118","article-title":"PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'","volume":"70","author":"Gonzalez","year":"2017","journal-title":"Histopathology"},{"key":"2025092506042897000_72.1.20.19","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.41","article-title":"Clinical and histologic mimickers of celiac disease","volume":"8","author":"Kamboj","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"2025092506042897000_72.1.20.20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv227"},{"key":"2025092506042897000_72.1.20.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"2025092506042897000_72.1.20.22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11523-017-0526-1","article-title":"The current landscape of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer: emerging treatment paradigms and future directions","volume":"12","author":"Qin","year":"2017","journal-title":"Target Oncol"},{"issue":"Suppl 1","key":"2025092506042897000_72.1.20.23","first-page":"S11","article-title":"Molecular testing to optimize therapeutic decision making in advanced colorectal cancer","volume":"7","author":"Semrad","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"2025092506042897000_72.1.20.24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"2025092506042897000_72.1.20.25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/187446720701150105171219","article-title":"Molecular testing and personalized treatment of lung cancer","volume":"7","author":"Sampsonas","year":"2014","journal-title":"Curr Mol Pharmacol"},{"key":"2025092506042897000_72.1.20.26","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J Thorac Dis"},{"key":"2025092506042897000_72.1.20.27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/PAP.0000000000000166","article-title":"Surgical pathology of gastrointestinal stromal tumors: practical implications of morphologic and molecular heterogeneity for precision medicine","volume":"24","author":"Charville","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"2025092506042897000_72.1.20.28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14740\/wjon1019w","article-title":"The era of multigene panels comes? The clinical utility of Oncotype DX and Mammaprint","volume":"8","author":"Xin","year":"2017","journal-title":"World J Oncol"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2018-205370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:04:38Z","timestamp":1758805478000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2018-205370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,13]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/jclinpath-2018-205370"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2018-205370","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}